Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients

Breast Cancer Research and Treatment

Volumn 130, Issue 3, 2011, Pages 863-870

  Lee, Seung Ah ^a   Hwang, Seung Hyun ^a   Ahn, Sung Gwe ^a   Lee, Hak Min ^a   Jeong, Joon ^a   Lee, Hy De ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Aromatase inhibitor; Bone loss; Bone mineral density; Breast cancer; Postmenopausal women; Zoledronic acid

Indexed keywords

ANASTROZOLE; LETROZOLE; ZOLEDRONIC ACID;

ADULT; AGE DISTRIBUTION; AGED; AMENORRHEA; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; ETHNIC GROUP; FEMALE; HIP; HUMAN; KOREAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MONOTHERAPY; OSTEOLYSIS; OSTEOPENIA; OUTCOME ASSESSMENT; OVARY INSUFFICIENCY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

ADULT; AGED; AROMATASE INHIBITORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; KOREA; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE;

EID: 82255175013     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1728-3     Document Type: Article

References (22)

1. M Baum AU Budzar J Cuzick J Forbes JH Houghton JG Klijn T Sahmoud 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139 12090977 10.1016/S0140-6736(02)09088-8 1:CAS:528:DC%2BD38XkslGhsLY%3D (Pubitemid 34694019)
2. A Howell J Cuzick M Baum A Buzdar M Dowsett JF Forbes G Hoctin-Boes J Houghton GY Locker JS Tobias 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62 10.1016/S0140-6736(04)17666-6 15639680 10.1016/S0140-6736(05)74803-0 1:STN:280:DC%2BD2M%2FhsVartA%3D%3D (Pubitemid 40082147)
3. B Thurlimann A Keshaviah AS Coates H Mouridsen L Mauriac JF Forbes R Paridaens M Castiglione-Gertsch RD Gelber M Rabaglio I Smith A Wardley KN Price A Goldhirsch 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757 16382061 10.1056/NEJMoa052258 (Pubitemid 43016814)
4. A Buzdar A Howell J Cuzick C Wale W Distler G Hoctin-Boes J Houghton GY Locker JM Nabholtz 2006 Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 633 643 10.1016/S1470-2045(06)70767-7 16887480 10.1016/S1470-2045(06)70767-7 1:STN:280:DC%2BD28vmsVOmsQ%3D%3D (Pubitemid 44123570)
5. A Ibrahim N Scher G Williams R Sridhara N Li G Chen J Leighton B Booth JV Gobburu A Rahman Y Hsieh R Wood D Vause R Pazdur 2003 Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases Clin Cancer Res 9 2394 2399 12855610 1:CAS:528:DC%2BD3sXlt1ykur4%3D (Pubitemid 36842077)
6. MF Gnant B Mlineritsch G Luschin-Ebengreuth S Grampp H Kaessmann M Schmid C Menzel JC Piswanger-Soelkner A Galid M Mittlboeck H Hausmaninger R Jakesz 2007 Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group J Clin Oncol 25 820 828 10.1200/JCO.2005.02.7102 17159195 10.1200/JCO.2005.02.7102 1:CAS:528:DC%2BD2sXjvVKmtLw%3D (Pubitemid 350002882)
7. NJ Bundred ID Campbell N Davidson RH DeBoer H Eidtmann A Monnier P Neven G von Minckwitz JC Miller NL Schenk RE Coleman 2008 Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results Cancer 112 1001 1010 10.1002/cncr.23259 18205185 10.1002/cncr.23259 1:CAS:528:DC%2BD1cXjs1eqsLs%3D (Pubitemid 351304583)
8. JA Cauley 2011 Defining ethnic and racial differences in osteoporosis and fragility fractures Clin Orthop Relat Res 469 7 1891 1899 10.1007/s11999-011- 1863-5 21431462 10.1007/s11999-011-1863-5
9. RE Coleman JJ Body JR Gralow A Lipton 2008 Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies Cancer Treat Rev 34 Suppl 1 S31 S42 10.1016/j.ctrv.2008.03.005 18486346 10.1016/j.ctrv.2008.03.005 1:CAS:528:DC%2BD1cXmvVOnsrg%3D
10. R Eastell RA Hannon J Cuzick M Dowsett G Clack JE Adams 2006 Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230) J Bone Miner Res 21 1215 1223 10.1359/jbmr.060508 16869719 10.1359/jbmr.060508 1:CAS:528:DC%2BD28XotlKrsL8%3D (Pubitemid 44128334)
11. CL Shapiro J Manola M Leboff 2001 Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer J Clin Oncol 19 3306 3311 11454877 1:CAS:528:DC%2BD3MXlvVamsr4%3D (Pubitemid 32642182)
12. Jeong J, The Korean Breast Cancer Society (2006) Nationwide Korean Breast Cancer Data of 2004 Using Breast Cancer Registration Program. The Korean Breast Cancer Society. J Breast Cancer 9:151-161
13. LC Hofbauer S Khosla CR Dunstan DL Lacey TC Spelsberg BL Riggs 1999 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells Endocrinology 140 4367 4370 10465311 10.1210/en.140.9.4367 1:CAS:528:DyaK1MXlslSqsLw%3D (Pubitemid 30647136)
14. J Geisler PE Lonning 2010 Impact of aromatase inhibitors on bone health in breast cancer patients J Steroid Biochem Mol Biol 118 294 299 10.1016/j.jsbmb.2009.10.004 19833206 10.1016/j.jsbmb.2009.10.004 1:CAS:528:DC%2BC3cXitlSlu78%3D
15. EA Perez RG Josse KI Pritchard JN Ingle S Martino BP Findlay TN Shenkier RG Tozer MJ Palmer LE Shepherd S Liu D Tu PE Goss 2006 Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 J Clin Oncol 24 3629 3635 10.1200/JCO.2005.05.4882 16822845 10.1200/JCO.2005.05.4882 1:CAS:528:DC%2BD28XovVSjsLc%3D (Pubitemid 46630537)
16. S Jones C Stokoe M Sborov M Braun S Ethirajan L Kutteh J Pippen M Patel D Paul JL Blum FA Holmes MC Myron J Cantrell NL Hartung RM Look E Di Salle JC Davis D Ilegbodu L Asmar 2008 The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer Clin Breast Cancer 8 527 532 10.3816/CBC.2008.n.065 19073509 10.3816/CBC.2008.n.065 1:CAS:528: DC%2BD1MXhtVGiu7k%3D
17. S Hong YH Ahn WH Choi 2010 Age-, gender- and region- related changes in bone mineral density of Korean adult (2003~2004) J Korean Soc Osteoporos 8 188 195
18. M Okishiro T Taguchi SJ Kim Y Tanji K Shimazu Y Tamaki S Noguchi 2009 Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole J Cancer Res Clin Oncol 135 823 827 10.1007/s00432-008-0518-8 19034512 10.1007/s00432-008-0518-8 1:CAS:528:DC%2BD1MXlt1Slu7w%3D
19. HC Zhang K Kushida K Atsumi K Kin A Nagano 2002 Effects of age and menopause on spinal bone mineral density in Japanese women: a ten-year prospective study Calcif Tissue Int 70 153 157 10.1007/s00223-001-1037-7 11907711 10.1007/s00223-001-1037-7 1:CAS:528:DC%2BD38XjtVOisrY%3D (Pubitemid 36929594)
20. M Gnant B Mlineritsch G Luschin-Ebengreuth F Kainberger H Kassmann JC Piswanger-Solkner M Seifert F Ploner C Menzel P Dubsky F Fitzal V Bjelic-Radisic G Steger R Greil C Marth E Kubista H Samonigg P Wohlmuth M Mittlbock R Jakesz 2008 Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Lancet Oncol 9 840 849 10.1016/S1470-2045(08)70204-3 18718815 10.1016/S1470-2045(08)70204-3 1:CAS:528:DC%2BD1cXhtVOiurnL
21. E Barrett-Connor ES Siris LE Wehren PD Miller TA Abbott ML Berger AC Santora LM Sherwood 2005 Osteoporosis and fracture risk in women of different ethnic groups J Bone Miner Res 20 185 194 10.1359/JBMR.041007 15647811 10.1359/JBMR.041007
22. LM Marshall JM Zmuda BK Chan E Barrett-Connor JA Cauley KE Ensrud TF Lang ES Orwoll 2008 Race and ethnic variation in proximal femur structure and BMD among older men J Bone Miner Res 23 121 130 10.1359/jbmr.070908 17892375 10.1359/jbmr.070908